Fri, Aug 29, 2014, 5:46 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • snt951 snt951 Aug 7, 2013 5:15 PM Flag

    CC (After hours)

    It sounded like there are many exciting and positive developments on the horizon (The European approvals keep coming). The Viropharma incident was the only negative; it will be steady growth going forward....the Pancreatic cancer program sounds very exciting to say the least and the relationships with Baxter and Pfizer are very solid to date.

    I am interested on other thoughts regarding the PPS; seems to be undervalued at this time?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Very undervalued at this point IMO. Per Frost on CC, paraphrased, "We remain in constant contact with all regulatory agencies regarding all our programs and no concern has been expressed about any current program."

      Mgt was very upbeat and positive. Outlook seems bright and PPS seems undervalued. Bought back a new position today going into earnings. Shorts will start to cover IMO due to catalysts moving forward and potential for Mabthera CHMP approval in August.

      Lots of biotechs getting beat up heading into earnings because no one wants to get caught by surprise. Happened with ARNA the other day as well and it was green today and moving off it's lows.

      Sentiment: Strong Buy

    • skeesby@verizon.net skeesby Aug 7, 2013 5:19 PM Flag

      They sounded very pleased with the Pfizer relationship. It seemed they really wanted to tell us something...but couldn't.

    • seriously undervalued, and a fraction of what it will bin a year from now

 
HALO
9.50+0.04(+0.42%)Aug 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.